Table 1.
Patient baseline characteristics
| Variable | Mean (range) or number of patients (%) |
|---|---|
| Age, years | 63.9 (33–86) |
| Gender | |
| Male | 37 (72.5) |
| Female | 14 (27.5) |
| Disease stage at diagnosis | |
| IB | 1 (2.0) |
| IIA | 1 (2.0) |
| IIB | 2 (3.9) |
| IIIA | 5 (9.8) |
| IIIB | 4 (7.8) |
| IV | 38 (74.5) |
| Histology | |
| Squamous | 26 (51.0) |
| Adenocarcinoma | 18 (35.3) |
| Mixed | 4 (7.8) |
| Other | 3 (5.9) |
| EGFR | |
| Mutant | 5 (9.8) |
| Wild type | 46 (90.2) |
| PD‐L1 expression | |
| < 1% | 5 (9.8) |
| Low (1–49%) | 11 (21.6) |
| High (> 50%) | 23 (45.1) |
| Unknown | 12 (23.5) |
| Smoking status | |
| Never | 17 (33.3) |
| Former | 16 (31.4) |
| Current | 18 (35.3) |
| Number of prior regimens | |
| 0 | 4 (7.8) |
| 1 | 23 (45.1) |
| ≥ 2 | 24 (47.1) |
| ECOG | |
| 0 | 8 (15.7) |
| 1 | 34 (66.7) |
| 2 | 9 (17.6) |
| Agent | |
| Atezolizumab | 6 (11.8) |
| Nivolumab | 20 (39.2) |
| Pembrolizumab | 25 (49.0) |
| Metastatic sites before immunotherapy | |
| Pleural or pericardial metastasis | 23 (45.1) |
| Lung to lung (only) | 2 (3.9) |
| Distant metastasis | 16 (31.4) |
| No distant metastasis | 10 (19.6) |
| Number of cycles of immunotherapy | 5.69 (1–21) |
ECOG, Eastern Cooperative Oncology Group.